Back to Search Start Over

Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree

Authors :
Abraham J. Wu
Andreas Rimner
Ankit Modh
Kenneth E. Rosenzweig
Justin Haseltine
Andrew Jackson
Daphna Y. Gelblum
Ellen Yorke
Source :
Practical Radiation Oncology. 6:e27-e33
Publication Year :
2016
Publisher :
Elsevier BV, 2016.

Abstract

Stereotactic body radiation therapy (SBRT) is associated with excess toxicity following treatment of central lung tumors. Risk-adapted fractionation appears to have mitigated this risk, but it remains unclear whether SBRT is safe for all tumors within the central lung zone, especially those abutting the proximal bronchial tree (PBT). We investigated the dependence of toxicity on tumor proximity to PBT and whether tumors abutting the PBT had greater toxicity than other central lung tumors after SBRT.A total of 108 patients receiving SBRT for central lung tumors were reviewed. Patients were classified based on closest distance from tumor to PBT. Primary endpoint was SBRT-related death. Secondary endpoints were overall survival, local control, and grade 3+ pulmonary adverse events. We compared tumors abutting the PBT to nonabutting and those ≤1 cm and1 cm from PBT.Median follow-up was 22.7 months. Median distance from tumor to PBT was 1.78 cm. Eighty-eight tumors were primary lung and 20 were recurrent or metastatic; 23% of tumors were adenocarcinoma and 71% squamous cell. Median age was 77.5 years. Median dose was 4500 cGy in 5 fractions prescribed to the 100% isodose line. Eighteen patients had tumors abutting the PBT, 4 of whom experienced SBRT-related death. No other patients experienced death attributed to SBRT. Risk of SBRT-related death was significantly higher for tumors abutting the PBT compared with nonabutting tumors (P.001). Two patients with SBRT-related death received anti-vascular endothelial growth factor therapy and experienced pulmonary hemorrhage. Patients with tumors ≤1 cm from PBT had significantly more grade 3+ events than those with tumors1cm from PBT (P = .014).Even with risk-adapted fractionation, tumors abutting PBT are associated with a significant and differential risk of SBRT-related toxicity and death. SBRT should be used with particular caution in central-abutting tumors, especially in the context of anti-vascular endothelial growth factor therapy.

Details

ISSN :
18798500
Volume :
6
Database :
OpenAIRE
Journal :
Practical Radiation Oncology
Accession number :
edsair.doi.dedup.....2d07cc866537409e136ea0f7a9b9c2e3
Full Text :
https://doi.org/10.1016/j.prro.2015.09.012